Edwards Lifesciences Corp. unveiled a new option in its heart valve franchise on Tuesday. The Irvine-based valve maker’s Ascendra procedure uses an aortic heart valve replacement system that is less ...

Edwards TAVR data has a strong showing at NY Valves 2026 amid intense industry competition from Abbott Laboratories and Medtronic.

CHICAGO (Reuters) - Edwards Lifesciences Corp said a U.S. regulatory advisory panel will review on July 20 its application to sell a replacement heart valve that spares patients the need for ...

Edwards Lifesciences secures FDA clearance for its ECLIPTIS Left Atrial Appendage Exclusion System, entering a competitive ...

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

An analyst earlier this month took aim at what’s behind a big run-up in shares of Irvine medical device maker Edwards Lifesciences Corp.: a new type of heart valve that doesn’t require major surgery.

Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...